Drug Profile
Cervical cancer vaccine - Jiangsu Antae Biological Technology
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Jiangsu Antae Biological Technology
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cervical cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Cervical-cancer in China (Parenteral)
- 03 Aug 2016 Clinical trials in Cervical cancer in China (Parenteral)
- 03 Aug 2016 Jiangsu Antae Biotechnology plans a phase III trial for Cervical cancer in China (ChiCTR-OIC-16008915)